Skip to main content
NBIX
NASDAQ Life Sciences

Neurocrine Q2 Revenue Surges 39% to $959M; Soleno Acquisition Closed, $1B Credit Facility Secured

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$188.65
Mkt Cap
$18.652B
52W Low
$122.138
52W High
$186.12
52W Position info
54% above low
Off High info
at 52W high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

NBIX sits 54% above its 52-week low of $122.138.

Summary

Neurocrine Biosciences reported Q2 2026 revenue of $959M (+39% YoY) and net income of $144.4M, driven by strong product sales and the recent Soleno acquisition. The company also secured a $1B credit facility and continued share repurchases.


Key Events · Earnings and Guidance · NBIX

  • Q2 Revenue Hits $959M

    Total revenues surged 39% year-over-year to $959.0 million, with INGREZZA at $716.5M, CRENESSITY at $183.5M, and newly acquired VYKAT XR contributing $54.3M.

  • Net Income More Than Doubles

    Net income reached $144.4 million, or $1.39 per diluted share, compared to $107.5 million ($1.06) in Q2 2025, driven by revenue growth and a lower effective tax rate.

  • Soleno Acquisition Completed

    The $2.9 billion acquisition of Soleno Therapeutics closed on May 18, 2026, adding VYKAT XR for Prader-Willi syndrome and expanding the rare disease portfolio.

  • $1B Credit Facility Secured

    Entered into a five-year $1.0 billion senior secured revolving credit facility; no borrowings were outstanding as of June 30, 2026, providing significant financial flexibility.


Analysis · NBIX · Life Sciences

A standout quarter saw total revenues jump 39% year-over-year to $959 million, fueled by robust INGREZZA and CRENESSITY sales plus the addition of VYKAT XR from the newly closed Soleno acquisition. Net income more than doubled to $144.4 million, and the company secured a $1 billion revolving credit facility, providing ample liquidity. The period also featured continued share buybacks and the adoption of 10b5-1 trading plans by key executives. The only notable concern is a DOJ civil investigative demand regarding INGREZZA marketing practices, though the company is cooperating.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NBIX was trading at $188.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $122.14 to $186.12. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBIX - Latest Insights

NBIX
Nov 03, 2026, 2:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $168.29
Real-time Price: $150.54 info
Change: -$17.75 (-11%) info
Market Cap: $15.306B info
NBIX
Nov 02, 2026, 4:50 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $157.48
Real-time Price: $150.54 info
Change: -$6.94 (-4%) info
Market Cap: $15.306B info
NBIX
Nov 02, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $146.96
Real-time Price: $150.54 info
Change: +$3.58 (+2%) info
Market Cap: $15.306B info
NBIX
Nov 02, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $145.35
Real-time Price: $150.54 info
Change: +$5.19 (+4%) info
Market Cap: $15.306B info
NBIX
Aug 26, 2026, 3:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.37
Real-time Price: $150.54 info
Change: -$2.83 (-2%) info
Market Cap: $15.306B info